Karl M. Kilgore, PhD

Articles by Karl M. Kilgore, PhD

Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell Therapy

December 13th 2019

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.

Latest Updated Articles

Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell Therapy
Published: December 13th 2019 | Updated:

Karl M. Kilgore, PhD

Articles by Karl M. Kilgore, PhD

Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell Therapy

Latest Updated Articles

Trending on CGTlive®

Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA

Around the Helix: Cell and Gene Therapy Company Updates – December 17, 2025

What the Field of Cell and Gene Therapy Needs Most in the Current Moment

CGTLive®’s Weekly Rewind – December 19, 2025

Steven W. Pipe, MD, on the Implications of the Final Data From Hemgenix’s HOPE-B Trial